BRPI0811476A2 - Dosagem intravenosa e oral de um inibidor de p2y12 de ação direta e reversível - Google Patents
Dosagem intravenosa e oral de um inibidor de p2y12 de ação direta e reversívelInfo
- Publication number
- BRPI0811476A2 BRPI0811476A2 BRPI0811476-5A2A BRPI0811476A BRPI0811476A2 BR PI0811476 A2 BRPI0811476 A2 BR PI0811476A2 BR PI0811476 A BRPI0811476 A BR PI0811476A BR PI0811476 A2 BRPI0811476 A2 BR PI0811476A2
- Authority
- BR
- Brazil
- Prior art keywords
- reversible
- intravenous
- inhibitor
- direct
- oral dosage
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91564907P | 2007-05-02 | 2007-05-02 | |
US94792107P | 2007-07-03 | 2007-07-03 | |
PCT/US2008/062518 WO2008137753A2 (en) | 2007-05-02 | 2008-05-02 | Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0811476A2 true BRPI0811476A2 (pt) | 2014-11-04 |
Family
ID=39587015
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0811476-5A2A BRPI0811476A2 (pt) | 2007-05-02 | 2008-05-02 | Dosagem intravenosa e oral de um inibidor de p2y12 de ação direta e reversível |
Country Status (17)
Country | Link |
---|---|
US (2) | US20090048216A1 (pt) |
EP (1) | EP2079464A2 (pt) |
JP (1) | JP2010526101A (pt) |
KR (1) | KR20100029746A (pt) |
CN (1) | CN101795682A (pt) |
AU (1) | AU2008247483A1 (pt) |
BR (1) | BRPI0811476A2 (pt) |
CA (1) | CA2686203A1 (pt) |
CO (1) | CO6241104A2 (pt) |
EA (1) | EA200901473A1 (pt) |
EC (1) | ECSP099778A (pt) |
GT (1) | GT200900284A (pt) |
IL (1) | IL201834A0 (pt) |
MA (1) | MA31663B1 (pt) |
MX (1) | MX2009011843A (pt) |
TN (1) | TN2009000451A1 (pt) |
WO (1) | WO2008137753A2 (pt) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2627719C (en) * | 2005-11-03 | 2016-07-12 | Portola Pharmaceuticals, Inc. | [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto |
KR20090115953A (ko) * | 2007-03-06 | 2009-11-10 | 노파르티스 아게 | 염증성 또는 알레르기성 상태의 치료에 적합한 바이시클릭 유기 화합물 |
US20090156620A1 (en) * | 2007-05-02 | 2009-06-18 | Portola Pharmaceuticals, Inc. | [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto |
AU2008247457A1 (en) * | 2007-05-02 | 2008-11-13 | Portola Pharmaceuticals, Inc. | [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)-phenyl] -5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof |
US9427448B2 (en) * | 2009-11-11 | 2016-08-30 | The Medicines Company | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
EP2384196B1 (en) * | 2008-12-30 | 2017-09-13 | Johansson, Pär | Methods of identifying critically ill patients at increased risk of development of organ failure and compounds for the treatment hereof |
US10376532B2 (en) | 2009-11-11 | 2019-08-13 | Chiesi Farmaceutici, S.P.A. | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
EA028885B1 (ru) | 2009-11-11 | 2018-01-31 | Чиези Фармачеутичи С.П.А. | Способы лечения или предотвращения тромбоза стента и инфаркта миокарда (варианты) |
EP2515871B1 (en) * | 2009-12-23 | 2015-09-23 | ratiopharm GmbH | Solid pharmaceutical dosage form of ticagrelor |
US20130165459A1 (en) | 2010-01-12 | 2013-06-27 | Norvartis Pharma Ag | Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof |
WO2011137459A1 (en) * | 2010-04-30 | 2011-11-03 | Portola Pharmaceuticals, Inc. | Dosage forms of elinogrel and methods of injectable administration thereof |
WO2012072743A1 (en) * | 2010-12-01 | 2012-06-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method and kits for determining platelet susceptibility to activation in a patient |
JP2013544271A (ja) * | 2010-12-03 | 2013-12-12 | ポートラ ファーマシューティカルズ, インコーポレイテッド | 式(i)の化合物の薬学的組成物、投薬形態、および新規の形態、ならびにその使用方法 |
EP3595666A1 (en) | 2017-03-15 | 2020-01-22 | Idorsia Pharmaceuticals Ltd | Subcutaneous administration of a p2y12 receptor antagonist |
CA3060345A1 (en) | 2017-06-23 | 2018-12-27 | Chiesi Farmaceutici S.P.A. | Method of preventing of systemic-to-pulmonary-artery shunt thrombosis |
CN107462648B (zh) * | 2017-08-21 | 2019-09-27 | 盐城锦明药业有限公司 | 一种Cangrelor中间体腺苷-2-硫酮的高效液相色谱检测方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6906063B2 (en) | 2000-02-04 | 2005-06-14 | Portola Pharmaceuticals, Inc. | Platelet ADP receptor inhibitors |
CA2627719C (en) | 2005-11-03 | 2016-07-12 | Portola Pharmaceuticals, Inc. | [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto |
-
2008
- 2008-05-02 AU AU2008247483A patent/AU2008247483A1/en not_active Abandoned
- 2008-05-02 MX MX2009011843A patent/MX2009011843A/es not_active Application Discontinuation
- 2008-05-02 US US12/114,630 patent/US20090048216A1/en not_active Abandoned
- 2008-05-02 BR BRPI0811476-5A2A patent/BRPI0811476A2/pt not_active IP Right Cessation
- 2008-05-02 CA CA002686203A patent/CA2686203A1/en not_active Abandoned
- 2008-05-02 KR KR1020097025059A patent/KR20100029746A/ko not_active Application Discontinuation
- 2008-05-02 WO PCT/US2008/062518 patent/WO2008137753A2/en active Application Filing
- 2008-05-02 EA EA200901473A patent/EA200901473A1/ru unknown
- 2008-05-02 CN CN200880023071A patent/CN101795682A/zh active Pending
- 2008-05-02 EP EP08747561A patent/EP2079464A2/en not_active Withdrawn
- 2008-05-02 JP JP2010506688A patent/JP2010526101A/ja not_active Withdrawn
-
2009
- 2009-10-29 IL IL201834A patent/IL201834A0/en unknown
- 2009-10-30 TN TNP2009000451A patent/TN2009000451A1/fr unknown
- 2009-10-30 GT GT200900284A patent/GT200900284A/es unknown
- 2009-11-26 MA MA32377A patent/MA31663B1/fr unknown
- 2009-12-02 CO CO09137697A patent/CO6241104A2/es not_active Application Discontinuation
- 2009-12-02 EC EC2009009778A patent/ECSP099778A/es unknown
-
2011
- 2011-09-16 US US13/235,305 patent/US20120009172A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
GT200900284A (es) | 2012-01-31 |
WO2008137753A3 (en) | 2009-02-12 |
US20120009172A1 (en) | 2012-01-12 |
US20090048216A1 (en) | 2009-02-19 |
WO2008137753A2 (en) | 2008-11-13 |
EP2079464A2 (en) | 2009-07-22 |
AU2008247483A1 (en) | 2008-11-13 |
KR20100029746A (ko) | 2010-03-17 |
CA2686203A1 (en) | 2008-11-13 |
IL201834A0 (en) | 2010-06-16 |
MX2009011843A (es) | 2010-04-22 |
JP2010526101A (ja) | 2010-07-29 |
ECSP099778A (es) | 2010-01-29 |
CN101795682A (zh) | 2010-08-04 |
TN2009000451A1 (en) | 2011-03-31 |
CO6241104A2 (es) | 2011-01-20 |
MA31663B1 (fr) | 2010-09-01 |
EA200901473A1 (ru) | 2010-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0811476A2 (pt) | Dosagem intravenosa e oral de um inibidor de p2y12 de ação direta e reversível | |
DK2277509T3 (da) | DPP IV inhibitorformuleringer | |
CY2014012I2 (el) | Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης | |
BRPI0918360A2 (pt) | composto, composição farmacêutica e usos de um composto | |
DK2399579T3 (da) | Farmaceutiske doseringsformer | |
DK2073795T3 (da) | Misbrugssikret lægemiddelformulation | |
PT2397142T (pt) | Utilizações de inibidores da dpp iv | |
BRPI0720100A2 (pt) | Implemento para cuidado oral | |
DK2077729T3 (da) | Orale probiotiske doseringsformer | |
BRPI1011587A2 (pt) | compostos e composições terapèuticas | |
BRPI0716365A2 (pt) | "artigo odontolàgico" | |
GB0703438D0 (en) | Preventing spread of infection | |
BRPI0918206A2 (pt) | derivados de animoéster e composição medicinal destes | |
ATE493119T1 (de) | Pharmazeutische zusammensetzung | |
BRPI0819232A2 (pt) | composto heterocíclico e composição farmacêutica do mesmo | |
AP2627A (en) | New form of administration of racecadotril | |
DE602007010119D1 (de) | Mundpflegezusammensetzung mit silikonverbund | |
BRPI0810581A2 (pt) | Produto refratário fundido e moldado e utilização de um produto | |
IL202765A0 (en) | Pharmaceutical combination of nsaid and prostaglandin compound | |
DE602008005137D1 (de) | Chinolonverbindung und pharmazeutische zusammensetzung | |
BRPI0909211A2 (pt) | formulação orais e injetáveis de composto de tetraciclina | |
NO20083139L (no) | Anvendelse av hyllebærekstrakt | |
BRPI0912074A2 (pt) | composto e composição farmacêutica | |
ITTO20060201A1 (it) | Impianto dentario condizionante post-estrattivo | |
BRPI0923763A2 (pt) | composto, utilização de um composto e composição farmacêutica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A E 7A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
B350 | Update of information on the portal [chapter 15.35 patent gazette] |